Tagged: MS
Innovative Strategies Address Risks Related to Multiple Sclerosis Treatments
May 21st, 2019 | MSCategories
- Biomarkers & Surrogate Endpoints
- Company News
- Drug Development
- Due Diligence
- Early Clinical Development
- Industry News
- Medical Affairs and Clinical Research
- Miscellaneous
- Orphan Diseases
- Pre-IND
- Precision Medicine
- Rare Disease
- Real World Evidence
- Regulatory
- Regulatory Affairs
- Strategy and TPP
- Translation Medicine and Epigenetics
- Trial Management
- Trial Rescue
Recent Posts
- Is Your Drug Development Strategy Built for Tomorrow’s Success?
- BBCR assists companies with the identification and adoption of biomarkers, now a routine part of drug development, and especially valuable in rare disease and precision medicine product development. Reach out to us to learn how we can assist with your development project.
- Partnering with BBCR Consulting means gaining the support of a specialized team committed to making the clinical trial process more efficient.
- Who is BBCR and how do we help pharmaceutical innovators in the specialized rare diseases and orphan drug industries? We invite you to learn more at bbcrconsulting.com.
- Accelerate Drug Development with Biomarker Strategy in Orphan Diseases and Precision Medicine